US OptionsDetailed Quotes
SGMO241220P500
- 0.02
- 0.000.00%
15min DelayClose Nov 21 16:00 ET
0.00High0.00Low
0.02Open0.02Pre Close0 Volume3 Open Interest0.50Strike Price0.00Turnover310.93%IV75.51%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier29DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type-0.0224Delta0.0312Gamma98.00Leverage Ratio-0.0016Theta0.0000Rho-2.19Eff Leverage0.0003Vega
Sangamo Therapeutics Stock Discussion
Sign in to post a comment
$Rumble (RUM.US)$ $Red Cat Holdings (RCAT.US)$ $Microvision (MVIS.US)$ $Bit Digital (BTBT.US)$ $Wix.com (WIX.US)$ $Sangamo Therapeutics (SGMO.US)$ $Above Food Ingredients (ABVE.US)$ $Exicure (XCUR.US)$ $Hoth Therapeutics (HOTH.US)$ $Kingsoft Cloud (KC.US)$ $Digital Brands Group (DBGI.US)$ $Tevogen Bio Holdings (TVGN.US)$ $Nauticus Robotics (KITT.US)$ $Tonix Pharmaceuticals (TNXP.US)$
📊⚡️📊
📊⚡️📊
3
5
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Fresh2 (FRES.US)$ $Opus Genetics (IRD.US)$ $Sangamo Therapeutics (SGMO.US)$ $Kindly MD (KDLY.US)$ $Edesa Biotech (EDSA.US)$ $Sadot (SDOT.US)$ $Lazydays (GORV.US)$ $Zeo Energy (ZEO.US)$ $Hall Of Fame Resort & Entertainment (HOFV.US)$ $Nauticus Robotics (KITT.US)$ $KORE Group (KORE.US)$ $Digital Brands Group (DBGI.US)$ $Hoth Therapeutics (HOTH.US)$ $Tonix Pharmaceuticals (TNXP.US)$
📊⚡️📊
📊⚡️📊
4
$Sangamo Therapeutics (SGMO.US)$ Sangamo Therapeutics Gets FDA Clearance Of IND Application For ST-503 For Treatment Of Idiopathic Small Fiber Neuropathy
Benzinga· 3 mins ago
Benzinga· 3 mins ago
4
3
$Sangamo Therapeutics (SGMO.US)$
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo plans to initiate enrollment of patients in thePhase 1/2 study for ST-503 in mid-2025
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for i...
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Sangamo plans to initiate enrollment of patients in thePhase 1/2 study for ST-503 in mid-2025
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for i...
1
$Sangamo Therapeutics (SGMO.US)$
S-3: Registration statement for specified transactions by certain issuers
“This registration statement contains two prospectuses:
•
a base prospectus, which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $500,000,000 of the registrant’s common stock, preferred stock, debt securities and/or warrants from time to time in one or more offerings; and
•
a sales agreement prospectus, which cov...
S-3: Registration statement for specified transactions by certain issuers
“This registration statement contains two prospectuses:
•
a base prospectus, which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $500,000,000 of the registrant’s common stock, preferred stock, debt securities and/or warrants from time to time in one or more offerings; and
•
a sales agreement prospectus, which cov...
3
$Sangamo Therapeutics (SGMO.US)$ Third Quarter 2024 Financial Results
Consolidated net income available for common stockholders for the third quarter ended September 30, 2024 was $10.7 million, or $0.04 per share on a fully diluted basis, compared to a net loss of $104.2 million, or $0.59 per share, for the same period in 2023.
Revenues
Revenues for the third quarter ended September 30, 2024 were $49.4 million, compared to $9.4 million for the same period in 2023.
The increase of $40.0 millio...
Consolidated net income available for common stockholders for the third quarter ended September 30, 2024 was $10.7 million, or $0.04 per share on a fully diluted basis, compared to a net loss of $104.2 million, or $0.59 per share, for the same period in 2023.
Revenues
Revenues for the third quarter ended September 30, 2024 were $49.4 million, compared to $9.4 million for the same period in 2023.
The increase of $40.0 millio...
2
5
No comment yet
Andy-Lai OP : Trash stocks
WillLaw : patience grass hopper
Andy-Lai OP WillLaw : 几时哦
WillLaw Andy-Lai OP : when?
Andy-Lai OP WillLaw : Yes.
View more comments...